Anti-LINGO
Dyax licensee Biogen Idec Inc. (Biogen) has stated that their Phase 2 clinical trial in acute optic neuritis with anti-LINGO, a fully human monoclonal antibody that targets LINGO-1, is fully enrolled. Biogen has also stated that they expect to disclose top-line results from the study, which is referred to as RENEW, in early 2015.- In 2013, Biogen initiated a randomized, double-blind, parallel-group, dose-ranging Phase 2 clinical trial investigating anti-LINGO used concurrently with Avonex in subjects with relapsing forms of multiple sclerosis. Data from this study, which is referred to as SYNERGY, is expected in 2016.
